Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 135 stocks over the last week.</li>
<li>The average A/H premium changed by -0.9ppt week on week to 118.3%. </li>
<li>Biggest decline in A/H premium appeared in the Communication Services and Consumer Staples sector while the biggest increase was from the Real Estate sector</li>
</ul>


We analyse the changes of A/H premium on 135 stocks over the last week.
The average A/H premium changed by -0.9ppt week on week to 118.3%. 
Biggest decline in A/H premium appeared in the Communication Services and Consumer Staples sector while the biggest increase was from the Real Estate sector


A/H Premium Weekly: Decline in Com Service and Consumer Staple Offset by Real Estate

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Dec 31. </li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We note that short interests for Wuxi Biologics and Wuxi Apptec are going in opposite directions.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Dec 31. 
Top short increases and decreases were tabulated for one week and four week period. 
We note that short interests for Wuxi Biologics and Wuxi Apptec are going in opposite directions.


HK Short Interest: Wuxi Biologics and Wuxi Apptec

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>China attaches great importance to gene therapy and related products, which would be a leader of the third industrial revolution in biomedicine and have broad prospects for future development.</li>
<li>With obvious strength in this field,<a href="https://www.smartkarma.com/entities/genscript-biotech-corp" target="_blank" data-smartkarma-citation="entities:21041:1" rel="noopener">Genscript Biotech (1548 HK)</a>’s businesses are in line with the future trend and the outlook is also quite promising, indicating exponential growth potential in valuation.</li>
<li>However, the potential risks on deterioration of international relations and the concerns on CAR-T commercialization should not be neglected by investors.</li>
</ul>


China attaches great importance to gene therapy and related products, which would be a leader of the third industrial revolution in biomedicine and have broad prospects for future development.
With obvious strength in this field,Genscript Biotech (1548 HK)’s businesses are in line with the future trend and the outlook is also quite promising, indicating exponential growth potential in valuation.
However, the potential risks on deterioration of international relations and the concerns on CAR-T commercialization should not be neglected by investors.


Genscript Biotech (1548.HK) - The Strength and the Concerns

Porton Pharma Solutions / Equity Bottom-Up

<ul>
<li>Porton made a successful turnaround and the CGT business layout is also in the right direction. The US$217 million new order would improve the certainties of its 2022 performance.</li>
<li>The concerns on potential deterioration of international relations and the broken logic in CXO sector also apply to <a href="https://www.smartkarma.com/entities/porton-pharma-solutions-ltd" target="_blank" data-smartkarma-citation="entities:14201:1" rel="noopener">Porton Pharma Solutions (300363 CH)</a>, which should be aware of by investors.</li>
<li>So, there is a long way to go for Porton to truly get into the first tier. It may not be a good buying point currently considering the high valuation.</li>
</ul>


Porton made a successful turnaround and the CGT business layout is also in the right direction. The US$217 million new order would improve the certainties of its 2022 performance.
The concerns on potential deterioration of international relations and the broken logic in CXO sector also apply to Porton Pharma Solutions (300363 CH), which should be aware of by investors.
So, there is a long way to go for Porton to truly get into the first tier. It may not be a good buying point currently considering the high valuation.


Porton Pharma Solutions (300363.CH) - Not Easy to Get into the First Tier

Thematic (Sector/Industry)

<ul>
<li>For Pfizer,orders on COVID-19 vaccine and Paxlovid would generate over US$50 billion revenue in 2022. So whether Pfizer would pursue for new M&amp;A opportunities become the focus of the market.</li>
<li>The oral COVID-19 antivirals are a great opportunity for the development of Chinese API companies, improving the overall valuation. However, CXOs are actually the first to benefit from this market.</li>
<li>If the COVID mutates in a more transmissible direction, the valuation and forecast of related companies in this industrial chain needs readjustment.However, if it doesn’t, the logic would change again.</li>
</ul>


For Pfizer,orders on COVID-19 vaccine and Paxlovid would generate over US$50 billion revenue in 2022. So whether Pfizer would pursue for new M&amp;A opportunities become the focus of the market.
The oral COVID-19 antivirals are a great opportunity for the development of Chinese API companies, improving the overall valuation. However, CXOs are actually the first to benefit from this market.
If the COVID mutates in a more transmissible direction, the valuation and forecast of related companies in this industrial chain needs readjustment.However, if it doesn’t, the logic would change again.


Oral COVID-19 Antivirals and the Impact on China

China

WuXi AppTec Co., Ltd. manufactures medical products. The Company produces biological agents, antibodies, biological diagnostic reagents, and other products. WuXi AppTec also provides biological analysis, technical study, and other services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

WuXi AppTec (2359 HK)

A/H Premium Weekly: Decline in Com Service and Consumer Staple Offset by Real Estate

Biggest decline in A/H premium appeared in the Communication Services and Consumer Staples sector while the biggest increase was from the Real...

Ke Yan, CFA, FRM

HK Short Interest: Wuxi Biologics and Wuxi Apptec

We highlight that week-on-week short interests for Wuxi Biologics (2269 HK) and Wuxi Apptec (2359 HK) are going in opposite directions despite both...

Ke Yan, CFA, FRM

Genscript Biotech (1548.HK) - The Strength and the Concerns

This insight analyzed Genscript's three largest segments (life-science services and products, CDMO, cell therapy), strength in CGT, and concerns on...

Xinyao (Criss) Wang

Porton Pharma Solutions (300363.CH) - Not Easy to Get into the First Tier

This insight analyzed Porton about its past development, how it successfully made turnarounds, the future outlook, and concerns on deterioration of...

Xinyao (Criss) Wang

Oral COVID-19 Antivirals and the Impact on China

This insight analyzed Pfizer's Paxlovid and Merck’s Molnupiravir after FDA EUA, the global market potential, the impact on China market and related...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)